Cannacielo brings together the brightest minds in the industry, providing globally-connected, end-to-end products and services for all things cannabis. Our mission is to nurture nature’s potential and help transform the lives of people all over the world. We see cannabis as a catalyst for change – one which requires a global network of farmers, brands and providers all working together to increase accessibility and challenge misconception.
We are building a global network of facilities, services and partners. Our reach allows us to produce and distribute an extensive range of products worldwide, as well as help businesses launch locally and scale globally.
We see the science behind cannabis as a craft – one of precision, care and attention. We strive to be the best at every step, from investing in cutting edge technology and fully CGMP accredited facilities to building a pioneering in-house team of industry-leading strain masters and geneticists.
We operate at every stage of the supply chain with end-to-end capabilities. This allows us to bring better quality and more cost-effective products to market, operate effortlessly at scale, and formulate bespoke products to match regulatory and commercial needs.
We are at the forefront of research and development of minor cannabinoids, researching over 400 compounds suitable for a broad spectrum of applications. As well as THC and CBD, this includes other versatile cannabinoids such as CBG, CBN, CBC, THCV, and CBDV.
Our global network will be rolled out in three phases across four major territories. Phase one begins with Europe – specifically Greece and Macedonia – and will be complete by the end of 2021. Phase two will see us open facilities in the Americas (Antigua and St Vincent) and Africa (Mauritius, Ghana, and Togo). The expected completion date is 2022. By 2023, Phase three will have opened up markets in Asia, with a focus on Singapore and India.